Month: January 2026

Oslo, Norway (26 January 2026) – TGS, a leading global provider of energy data and intelligence will release its Q4 2025 results at approximately 07:00 a.m. CET on 12 February. CEO Kristian Johansen and CFO Sven Børre Larsen will present the results at 09:00 a.m. CET on 12 February at Thon Hotel Vika Atrium, Munkedamsveien 45, Oslo, Norway. The presentation is open to the public and will be webcasted live. Access and registration for webcast attendees are available by copying and pasting the link below into your browser, or use the link on the front page of www.tgs.com:https://qcnl.tv/p/miug3wdVpOfCTZvPDri7vw The Q4 2025 earnings release and presentation will be available on www.newsweb.no and www.tgs.com. For more information, visit TGS.com (http://www.tgs.com) or contact: Bård Stenberg, VP IR & Business Intelligence Mobile:...

Regulatory approvals for the remaining FF EAI Robotic products in the Company’s initial batch are advancing and are expected to be finalized soon. BlackRock increased its holdings in FFAI once again. According to its latest Schedule 13G filing, as of December 31, 2025, BlackRock held approximately 9.5 million shares of FFAI common stock, up from 6.8 million shares disclosed as of September 30, 2025 — an increase of about 40%. The FF EAI Robotics Product Final Launch and the FF/FX Par Partner Recruitment Conference will be held on February 4 in Las Vegas, at the National Automobile Dealers Association (NADA) ShowLOS ANGELES, Jan. 25, 2026 (GLOBE NEWSWIRE) — Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global shared intelligent electric mobility ecosystem...

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA action date set for May 24, 2026 TOKYO and CAMBRIDGE, Mass., Jan. 25, 2026 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai’s Supplemental Biologics License Application (sBLA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector (SC-AI), LEQEMBI IQLIK, as a weekly starting dose. LEQEMBI is indicated for the treatment of Alzheimer’s disease (AD) in patients with Mild Cognitive...

First surgeon-reported case using RECELL®, PermeaDerm®, and Cohealyx™ together in a single care pathwayNew clinical and tissue-level data on PermeaDerm and Cohealyx highlight wound bed preparation and readiness for closureRECELL analyses show consistent trends in healing, reduced complications, and shorter hospital stays across studies and real-world registry dataVALENCIA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) — AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced data from 19 scientific abstracts, including 14 podium presentations, at the 2026 Boswick Burn & Wound Symposium. The presentations include the first surgeon-reported integrated use of all three AVITA Medical technologies – RECELL, PermeaDerm, and Cohealyx...

This proposed capital raise is expected to fuel the prop-tech, asset-light HBNB business model towards its next growth stage of worldwide expansion SINGAPORE, Jan. 23, 2026 (GLOBE NEWSWIRE) — Hotel101 Global Holdings Corp. (NASDAQ: HBNB) (“HBNB,” “Hotel101 Global” or the “Company”) announced today that its board of directors (the “Board”) has approved the proposed intention to offer, subject to market conditions and other factors, perpetual convertible preferred shares (the “Preferred Shares”) to raise up to USD 300 million, in one or more private placements to persons reasonably believed to be “qualified institutional buyers” (as defined in Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”)) pursuant to Rule 144A under the Securities Act and/or in one or more registered offerings, subject to applicable...

BEIJING, Jan. 23, 2026 (GLOBE NEWSWIRE) — Leishen Energy Holding Co., Ltd. (“Leishen Energy”), a leading provider of clean-energy equipment and integrated solutions for the oil and gas industry, today announced that on January 16, 2026, it received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with Nasdaq Listing Rule 5620(a), which requires listed companies to hold an annual meeting of shareholders no later than one year after the end of the Company’s fiscal year. As stated in the Nasdaq letter, the Company did not hold an annual meeting of shareholders within twelve months following its fiscal year end and therefore no longer complies with the annual meeting requirement for continued listing on Nasdaq. The notification has no immediate effect on the listing...

VANCOUVER, British Columbia, Jan. 23, 2026 (GLOBE NEWSWIRE) — Wording in 3rd paragraph “Engagement of Michael Pound” has been corrected to reflect that Mr. Pound is no longer at arm’s length of the company. Domestic Metals Corp. (the “Company” or “Domestic”) – (TSXV: DMCU; OTCQB: DMCUF; FSE: 03E) announces that it has engaged the services of ICP Securities Inc. (“ICP”) to provide automated market making services, including use of its proprietary algorithm, ICP Premium™, in compliance with the policies and guidelines of the TSX Venture Exchange and other applicable legislation. ICP will be paid a monthly fee of C$7,500, plus applicable taxes. The agreement between the Company and ICP was signed with a start date of January 23, 2026 and is for four (4) months (the “Initial Term”) and shall be automatically renewed for...